Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-12059448-B2 · Aug 13, 2024 · US
US10967039B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10967039-B2 |
| Application number | US-201414894495-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 28, 2014 |
| Priority date | May 28, 2013 |
| Publication date | Apr 6, 2021 |
| Grant date | Apr 6, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion, wherein said miniemulsion comprises: (i) at least one alkyl cyanoacrylate monomer; (ii) at least two different polyalkylene glycols independently selected from the group consisting of polyethylene glycols (PEG), polypropylene glycols (PPG), and copolymers thereof; and (iii) optionally one or more active agents, wherein at least one of said polyalkylene glycols initiates the single step anionic polymerisation reaction. 2. The process for the preparation of nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer in claim 1 , wherein at least one of said polyalkylene glycols is covalently attached to a targeting moiety. 3. The process as claimed in claim 1 , wherein said miniemulsion is prepared by the addition of said at least two polyalkylene glycols to an oil-in water miniemulsion comprising said at least one alkyl cyanoacrylate monomer and optionally said one or more active agents. 4. The process as claimed in claim 3 , wherein said nanoparticles are stealth nanoparticles. 5. The process as claimed in claim 3 , wherein said miniemulsion further comprises a radically polymerisable crosslinker selected from the group consisting of an anhydride and an acrylate. 6. The process as claimed in claim 3 , wherein said at least one alkyl cyanoacrylate monomer is selected from the group consisting of ethyl cyanoacrylate, butyl cyanoacrylate, isohexyl cyanoacrylate, octyl cyanoacrylate and derivatives and mixtures thereof. 7. The process as claimed in claim 3 , wherein at least one of the polyalkylene glycols is a polyethylene glycol, optionally further comprising a hydrophobic component. 8. The process of claim 7 , wherein at least one of the polyethylene glycols is a block copolymer of a polyethylene glycol block and polypropylene glycol block and wherein said copolymer comprises a hydroxy or amino end group attached to the polypropylene glycol block. 9. The process of claim 3 wherein the targeting moieties are selected from the group consisting of peptides, miniproteins, antibody fragments, affibody molecules, nanobodies and aptamers. 10. The process of claim 3 , wherein the targeting moieties are selected from the group consisting of peptides, antibody fragments, affibody molecules, nanobodies and aptamers. 11. The process of claim 3 wherein the active agent is a therapeutic agent selected from the group consisting of docetaxel, cabazitaxel, paclitaxel, 5-fluorouracil, sorafenib, AMG900, temsirolimus or everolimus. 12. The process of claim 3 wherein the active agent is selected from the group consisting of carboplatin, oxaliplatin, picoplatin, tetraplatin, satraplatin, cisplatin, platinum-DACH and ormaplatin. 13. The process of claim 3 wherein the active agent is an imaging agent selected from the group consisting of metals, metal salts, near infrared dyes, fluorescent dyes, PET/SPECT chelating agents, agents suitable for MRI or Raman spectroscopy and radiopharmaceutical s.
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title
on to polyethers, polyoxymethylenes or polyacetals {(C08F283/004 takes precedence)} · CPC title
Ion exchange resins, e.g. polystyrene sulfonic acid resin · CPC title
Tripeptides · CPC title
Alpha-cyano-acrylic acid butyl ester · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.